These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 23192914)

  • 41. Solifenacin or mirabegron could improve persistent overactive bladder symptoms after dutasteride treatment in patients with benign prostatic hyperplasia.
    Maeda T; Kikuchi E; Hasegawa M; Ishioka K; Hagiwara M; Miyazaki Y; Shinojima T; Miyajima A; Oya M
    Urology; 2015 May; 85(5):1151-1155. PubMed ID: 25770728
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical and pressure-flow changes after long-term treatment with alfuzosin SR.
    De Nunzio C; Franco G; Iori F; Leonardo C; Minardi V; Laurenti C
    Urol Int; 2003; 71(1):31-6. PubMed ID: 12845257
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Therapy of benign prostatic hyperplasia with alpha receptor blockers].
    Stockamp K
    Urologe A; 1995 Jan; 34(1):3-8. PubMed ID: 7533449
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Comment to: «Cost-Effectiveness of the combination therapy of dutasteride and tamsulosin in the treatment of benign prostatic hyperlasia in Spain»].
    Miñana B
    Actas Urol Esp; 2011 Feb; 35(2):72. PubMed ID: 21324551
    [No Abstract]   [Full Text] [Related]  

  • 45. Doxazosin in men with lower urinary tract symptoms: urodynamic evaluation at 15 months.
    Gerber GS; Contreras BA; Zagaja GP; Kim JH; Steinberg GD; Rukstalis DB
    Urology; 1997 Aug; 50(2):229-33. PubMed ID: 9255293
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy and safety of a fixed-dose combination of dutasteride and tamsulosin treatment (Duodart(®) ) compared with watchful waiting with initiation of tamsulosin therapy if symptoms do not improve, both provided with lifestyle advice, in the management of treatment-naïve men with moderately symptomatic benign prostatic hyperplasia: 2-year CONDUCT study results.
    Roehrborn CG; Oyarzabal Perez I; Roos EP; Calomfirescu N; Brotherton B; Wang F; Palacios JM; Vasylyev A; Manyak MJ
    BJU Int; 2015 Sep; 116(3):450-9. PubMed ID: 25565364
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The resolution of detrusor over activity after medical and surgical treatment in patients with bladder outlet obstruction.
    Sriplakich S; Promwatcharanon K
    J Med Assoc Thai; 2007 Nov; 90(11):2326-31. PubMed ID: 18181315
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of the dual 5alpha-reductase inhibitor, dutasteride, on serum testosterone and body mass index in men with benign prostatic hyperplasia.
    Hong SK; Min GE; Ha SB; Doo SH; Kang MY; Park HJ; Yoon CY; Jeong SJ; Byun SS; Lee SE
    BJU Int; 2010 Apr; 105(7):970-4. PubMed ID: 19793378
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Change in parameters before and after alpha-1-blocker therapy for men with lower urinary tract symptoms using color doppler ultrasound urodynamics: possible application for prediction of clinical outcome.
    Watanabe Y; Yokoyama T; Ozawa H; Nishiguchi J; Nose H; Kumon H
    Urol Int; 2004; 73(3):252-7. PubMed ID: 15539846
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Overactive bladder: pharmacological treatment.
    Truzzi JC; Silvinato A; Bernardo WM;
    Rev Assoc Med Bras (1992); 2017 Mar; 63(3):197-202. PubMed ID: 28489120
    [No Abstract]   [Full Text] [Related]  

  • 51. The effects of dutasteride or tamsulosin alone and in combination on storage and voiding symptoms in men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH): 4-year data from the combination of avodart and tamsulosin (CombAT) study.
    Woo H
    BJU Int; 2011 May; 107(9):1431. PubMed ID: 21518231
    [No Abstract]   [Full Text] [Related]  

  • 52. What are the predicting factors for the therapeutic effects of dutasteride in male patients with lower urinary tract symptoms? Investigation using a urodynamic study.
    Matsukawa Y; Kato M; Funahashi Y; Majima T; Yamamoto T; Gotoh M
    Neurourol Urodyn; 2017 Sep; 36(7):1809-1815. PubMed ID: 28102554
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cardiovascular effects of alpha-blockers for the treatment of symptomatic BPH.
    de Mey C
    Eur Urol; 1998; 34 Suppl 2():18-28; discusion 47. PubMed ID: 9732829
    [No Abstract]   [Full Text] [Related]  

  • 54. [Alpha adrenergic blocking agents in disorders of the bladder sphincter].
    Perrigot M; Vannier A; Bor Y
    Rev Prat; 1986 Jan; 36(5):223-8. PubMed ID: 2421393
    [No Abstract]   [Full Text] [Related]  

  • 55. [Established and upcoming new options in medical therapy for benign prostatic hyperplasia].
    Schlenker B; Beer AM; Gratzke C; Tilki D; Seitz M; Stief CG; Reich O
    MMW Fortschr Med; 2009 Oct; 151(41):33-6. PubMed ID: 19891182
    [No Abstract]   [Full Text] [Related]  

  • 56. Dutasteride improves objective and subjective disease measures in men with benign prostatic hyperplasia and modest or severe prostate enlargement.
    Gittelman M; Ramsdell J; Young J; McNicholas T
    J Urol; 2006 Sep; 176(3):1045-50; discussion 1050. PubMed ID: 16890688
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dutasteride for the treatment of benign prostatic hyperplasia.
    Wu C; Kapoor A
    Expert Opin Pharmacother; 2013 Jul; 14(10):1399-408. PubMed ID: 23750593
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dutasteride/tamsulosin fixed-dose combination for the treatment of benign prostatic enlargement.
    Ismail M; Hashim H
    Drugs Today (Barc); 2012 Jan; 48(1):17-24. PubMed ID: 22384457
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Editorial comment on: Intraprostatic and bladder-neck botulinum A toxin in treatment of males with bladder-neck dyssynergia: a pilot study.
    Michel M
    Eur Urol; 2008 Mar; 53(3):626-7. PubMed ID: 17950523
    [No Abstract]   [Full Text] [Related]  

  • 60. Early effect of dutasteride added to alpha-1 blocker therapy for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia.
    Araki K; Naya Y; Inahara M; Suzuki F; Ota S; Tsuji H; Mikami K; Yanagisawa M; Awa Y; Suzuki H
    Int J Urol; 2014 Aug; 21(8):815-9. PubMed ID: 24735081
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.